Bringing doctors together

or

A free, private network for verified physicians

Leading voices

Dr. Drew Moghanaki

Thoracic Rad Onc · UCLA

View

Dr. Himanshu Nagar

GU Rad Onc · MSK

View

Dr. Michael Dykstra

General Rad Onc · UM

View

Dr. Lori Pierce

Breast Rad Onc · UM

View

Dr. William Hwang

GI Rad Onc · MGH

View

Dr. Kamran Ahmed

Breast Rad Onc · Moffitt Cancer Center

View

Dr. James Janopaul-Naylor

GU Rad Onc · MSK

View

Dr. Philip Schauer

Bariatric Surgery · PBRC

View

Dr. Justin Hovey, FAAP, FACP, DABOM

Obesity Medicine · Noland Hospital Dothan II

View

Dr. Kimberly Gudzune

Obesity Medicine · JHU

View
  • Discover your community

  • Stay current

  • A profile that represents you

  • Find your people

About RoonPrivacyTerms

    Overview

    Arterial Spin Labeling-Derived Fractional Tumor Burden as a Primary Biomarker for Differentiating Recurrent Tumor from Radiation Necrosis After Stereotactic Radiosurgery.

    Aug 5, 2026DOI: 10.3174/ajnr.a9569Journal ArticleAJNR

    Written by: Rafail ChristodoulouElham RahimyErqi Liu PollomMelanie Hayden GephartSeema NagpalScott SoltysMichael Iv

    Find these authors on Roon

    ER
    Dr. Elham Rahimy
    CNS Rad Onc · Stanford

    Summary

    BACKGROUND AND PURPOSE: Differentiating recurrent tumor from radiation necrosis after stereotactic radiosurgery remains a challenge with conventional MRI. Fractional tumor burden, a voxel-level perfusion biomarker originally developed using DSC-MRI, characterizes intralesional perfusion heterogeneity and has demonstrated good performance and improved interrater agreement in diagnostic interpretations over conventional perfusion metrics. We evaluated arterial spin labeling-derived fractional tumor burden for distinguishing tumor recurrence from radiation necrosis in treated brain metastases.MATERIALS AND METHODS: This retrospective study included 86 patients with 102 brain metastases (68 radiation necrosis, 34 tumor) evaluated with arterial spin labeling-MRI after stereotactic radiosurgery. Ground truth was based on histopathology or clinico-radiologic follow-up. The primary endpoint was fractional tumor burden-high voxel percentage (absolute and normalized). Secondary endpoints included fractional tumor burden-low, mean CBF, maximum CBF, and delta T1. Absolute CBF thresholds of ≤50 and ≥80 mL/100 g/min and normalized thresholds of ≤1.0 and ≥1.4 were defined a priori from prior histopathology-informed data. Diagnostic performance was assessed by receiver operating characteristic analysis and DeLong testing. Between-group comparisons used Mann-Whitney U tests; generalized linear mixed-effects models assessed logistic regression.RESULTS: Normalized fractional tumor burden-high demonstrated good discrimination of tumor from radiation necrosis, with area under the curve 0.81 (95% CI 0.71-0.90), sensitivity 0.79 (95% CI 0.63-0.94), specificity 0.74 (95% CI 0.61-0.86), PPV 0.60 (95% CI 0.43-0.77), and NPV 0.88 (95% CI 0.77-0.96), numerically outperforming absolute fractional tumor burden-high (area under the curve 0.75; 95% CI 0.66-0.84), although the difference was not significant (P = 0.22). Secondary arterial spin labeling-derived metrics demonstrated comparable performance (area under the curves = 0.79-0.83). Normalized fractional tumor burden-high significantly outperformed delta T1 (change in area under the curve = 0.19; 95% CI 0.05-0.31; P = 0.004). Logistic regression confirmed a monotonic association between normalized fractional tumor burden-high and tumor probability (OR = 1.62 per 10% increase; 95% CI 1.33-2.38; P = 0.001).CONCLUSIONS: Arterial spin labeling-derived fractional tumor burden-high provides good lesion-level differentiation between recurrent brain metastases and radiation necrosis after stereotactic radiosurgery, performing comparably to conventional CBF metrics. The voxel-level approach offers a clinically interpretable perfusion biomarker suitable for post-treatment response assessment.
    ERDr. Elham Rahimy

    Dr. Elham Rahimy

    Radiation Oncology · Central Nervous System Cancer Radiation Oncology
    Stanford Medicine
    elham